On June 15, 2023, Verve Therapeutics announced a research collaboration with Eli Lilly and Company (Lilly) focused on advancing Verve’s preclinical stage in vivo gene editing program targeting lipoprotein(a) (Lp(a)). Elevated Lp(a) is an established and genetically validated, independent risk factor for atherosclerotic cardiovascular disease (ASCVD), ischemic stroke, thrombosis and aortic stenosis. Under the terms of the agreement, Verve will advance the research and development of the Lp(a) program through the completion of Phase 1 clinical development. Verve will receive an upfront payment of $60 million, including a $30 million equity investment. Verve’s program cost through Phase 1 clinical trials will be funded by Lilly, and Verve is eligible to receive research, development, and commercial milestones, as well as tiered royalties on global net sales.

The WilmerHale team representing Verve in the collaboration with Lilly was led by Sarah Hogan and Scott Forman. The WilmerHale team representing Verve in the equity investment by Lilly was led by Craig Hilts, Andrea Sorrentino and Alex Bloom.